Feature: Profiting From Controversy - The Vioxx Trade(s).
No ratings
Feature: Profiting From Controversy - The Vioxx Trade(s). There's little doubt that the Vioxx controversy has been bad for everyone: patients, families, Merck, (NYSE: MRK) its shareholders, the drug sector and the markets. In no way is this piece biased